Mark Strobeck, Ph.D. is President and Chief Executive Officer at Rockwell Medical. Dr. Strobeck has held leadership positions in both emerging biotechnology and pharmaceutical companies for more than twenty years.

Most recently, he served as Managing Director of Aquilo Partners, LP, a life sciences investment bank. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla’s Chief Business Officer. He served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc.. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P.

Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati and completed his post-doctoral fellowship at the University of Pennsylvania.


Tim Chole is Senior Vice President, Sales and Marketing at Rockwell Medical. Mr. Chole brings over two decades of experience in commercial leadership roles for pharmaceutical and medical device companies. He has a proven track record of success launching products and growing mature portfolios; many of which have been therapeutics or devices for treatment of renal disease. Early in his career he served as the marketing lead for the IV iron portfolio at Watson Pharmaceuticals (now Allergan), and later was the Global Marketing Director for AKI Therapy at Gambro AB (now Baxter International Inc.). Mr. Chole's background includes global, international, and U.S. marketing leadership and market development roles. Most recently served the Director of Product Marketing and Professional Education for hearing implants at Cochlear Americas.

Throughout his distinguished career, Mr. Chole has demonstrated expertise in strategic planning, product marketing excellence, new market development, KOL engagement, product launches, and commercial execution.

Mr. Chole received a Bachelor of Science degree in managerial economics from the University of California at Davis.


Heather R. Hunter is Senior Vice President, Chief Corporate Affairs Officer at Rockwell Medical. In this role, Ms. Hunter is responsible for the Company’s investor relations, media relations, communications, branding, government affairs, and patient advocacy. 

Ms. Hunter brings more than two decades of executive leadership, investor relations and communications expertise to Rockwell, with a wealth of experience in the capital markets and a strong network across the financial community. She has a demonstrated track record of success elevating corporate brands, developing and implementing corporate strategy, and driving shareholder value.

Prior to joining Rockwell, Ms. Hunter led communications at Venatorx Pharmaceuticals, a private, pre-commercial anti-infectives pharmaceutical company; Safeguard Scientifics (NYSE:SFE), a growth equity investor focused on early- and growth-stage healthcare and technology companies; and W.P. Carey (NYSE:WPC), one of the largest net lease real estate investment trusts. Ms. Hunter was named to the Philadelphia Business Journal ‘40 Under 40’ list in 2017 and received a B.A. in History from Yale University.


Paul E. McGarry, CPA is Senior Vice President, Finance and Chief Accounting Officer at Rockwell Medical. In this role, Mr. McGarry leads the Company’s financial reporting, accounting and related internal controls functions. Mr. McGarry was promoted to this role in October 2022, having previously served as the Company’s Vice President, Corporate Controller and Principal Accounting Officer since June 2019.

Prior to joining Rockwell, Mr. McGarry served as Corporate Financial Controller at Alyvant, Inc., a healthcare company, where he was responsible for oversight of Alyvant’s financial management. Previously, Mr. McGarry served as Corporate Controller at Champions Oncology, Inc., a pharmaceutical company focused on the development of oncology drug products, where he was responsible for the oversight of Champions’ accounting and financial operations.

Mr. McGarry began his accounting career at Deloitte & Touche LLP, serving as Audit Manager in Assurance and Advisory Services, where he was tasked with implementing worldwide Sarbanes-Oxley procedures and performed Sarbanes-Oxley training for international audit teams. Mr. McGarry earned a B.S. in Accounting from Penn State and is a Certified Public Accountant in the state of New York.


Megan Timmins is Executive Vice President, Chief Legal Officer and Secretary at Rockwell Medical. With over twenty years of legal experience, including six years in the life sciences industry, Ms. Timmins has served in this role at Rockwell since August 2021. Previously, she served as Senior Vice President, General Counsel, and Corporate Secretary at Assertio Holdings, Inc. and Zyla Life Sciences (formerly Egalet Corporation), both publicly traded pharmaceutical companies. Ms. Timmins also held a high-level legal role at Aramark (NYSE: ARMK) as Vice President, Associate General Counsel and Assistant Corporate Secretary. Early in her legal career, she worked in private practice, including with Morgan, Lewis & Bockius, LLP.

Ms. Timmins holds a B.A. from the University of Notre Dame and a J.D. from William and Mary Law School.